Looking at the wider impact of the Sanofi-Genzyme deal
This article was originally published in Scrip
Executive Summary
After nearly nine months of informal and formal discussion, Sanofi-Aventis finally succeeded in persuading Genzyme's board that the company and its stakeholders would be better off as part of the French pharma giant. As the empty champagne bottles are collected for recycling, the conclusion of the negotiations throws up a whole new raft of questions related to the future of the biotech Industry.